Council discusses MCO coverage for sickle cell, high-cost treatments
An advisory council charged with proposing Medicaid financing models for expensive therapies that treat sickle cell disease and other high-cost drugs and treatments held discussions last week on what role managed care organizations play in coverage.
To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.
